Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hyaluronoglucosaminidase × Thoracic × Clear all
NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡